Welcome to the Cannabis Countdown, the Legal Marijuana Industry’s Number One Curated Weekly News Recap.
In This Week’s Edition, We Recap and Countdown the Top 10 Cannabis and Psychedelic Stock News Stories for the Week of April 19th – 25th, 2021.
Without further ado, let’s get started.
10. Supreme Acquisition Has Canada’s Largest Cannabis LP Poised to Grow already Bigger
Canopy Growth, Canada’s Largest Cannabis Licensed Producer Appears Set to for Another Major Growth Spurt Following the Company’s Suprise Announcement That it Would Be Acquiring competitor LP Supreme Cannabis
Canopy Growth (TSX: WEED) (NYSE: CGC) (FRA: 11L1) announced recently that it would be acquiring Supreme Cannabis (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) for a cool $435 million. It’s a slightly disinctive move, as Canopy Growth has been divesting, not acquiring, Canadian assets recently. Reaction from investors has been muted, as the stock price has not seen a large swing in either direction since the deal was announced.
READ complete WEED + FIRE ARTICLE
9. Champignon Brands Announces Revocation of Cease Trade Orders
Following the Revocation of the Cease Trade Orders and the CSE’s Acceptance of Champignon’s New Listing Statement, the Company’s shared Shares Recommenced Trading on the CSE
Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FRA: 496) announced that the British Columbia Securities Commission and Ontario Securities Commission revoked their cease trade orders against the company effective April 22, 2021. “We are pleased to be moving forward with a strengthened team and focus on governance. We have successfully progressive our business strategy to establish a network of clinics designed to provide rapid-acting treatments for adults with depression,” said Dr. Roger McIntyre, Chairman and CEO. “Depression is known to be one of the most disabling conditions across Canada and around the world. In addition, we have also been able to improvement our research and development towards discovering novel drug treatments for individuals affected by depression.”
READ complete SHRM ARTICLE
8. #MSOGang: Consider Buying the Warrants of These U.S. Pot Stocks Ahead of the Next Marijuana Market Rally
Stock Warrants Function in Much the Same Way That Stock Options Do, Giving the Owner the Right to Buy or Sell Shares of a Company at a Specific Price
Where options and warrants defer is where the money goes when the contract is exercised. While options trade on exchanges and all the money is going between investors, shares associated with warrants will be newly issued by the company. So warrants provide the company with additional funding supplies when exercised, while investors reap the reward of buying additional discounted shares. If the warrants are being exercised, it’s usually a win-win situation, as the company’s proportion price has usually risen a meaningful amount (and they get the cash). The investor makes a nice gain on their investment. Let’s take a closer look at the warrants of top U.S. Multi-State Operators (MSOs) Red White & Bloom (CSE: RWB) (OTCQX: RWBYF), Cresco Labs (CSE: CL) (OTCQX: CRLBF), Ayr Strategies (CSE: AYR.A) (OTCQX: AYRSF) and Trulieve (CSE: TRUL) (OTCQX: TCNNF).
READ complete MSO WARRANTS ARTICLE
7. 3 of the Top Psychedelic Stocks That Will Blow Your Mind
It’s No Secret That 2020 Was a Turning Point for Psychedelic Stocks in the Eyes of Investors and the Pandemic Has Precipitated a Heightened Focus on Mental Health and the Inadequacies of Our Current Standards of Care
The psychedelics market is on track to keep commanding investor attention this year. However, companies must continue delivering results and proving their worth with various mental health conditions. The first listing of a psychedelic pharmaceutical company was a landmark event for the industry in 2020. According to research, the industry is expected to grow at a enormous 15.8% from 2020 to 2027. With that being said, let’s look at three of the top psychedelics that are making groups at this time.
- Compass Pathways (NASDAQ: CMPS)
- MindMed (NEO: MMED) (NASDAQ: MNMD) (FRA: MMQ)
- Numinus Wellness (TSXV: NUMI) (OTC: LKYSD) (FRA: LR23)
READ complete PSYCHEDELIC STOCKS ARTICLE
6. Cronos Group is Undervalued, Says Raymond James
In the Update, Raymond James Analyst Rahul Sarugaser Maintained His “Outperform 2” Rating and $11 CRON Target Price
Cronos Group (TSX: CRON) (NASDAQ: CRON) (FRA: 7CI) saw its proportion price spike earlier this year, but the stock has now been on a prolonged slide since mid-February. Is there upside from here? Likely, says Raymond James analyst Rahul Sarugaser, who in a Friday client report previewed the company’s upcoming quarterly release, saying Cronos’ cannabinoid biosynthesis investments are about to pay off.
READ complete CRON ARTICLE
5. Cybin Selects Alcohol Use Disorder Indication for Psychedelic Molecule CYB003
Approximately 5.8% or 14.4 Million Adults in the United States Ages 18 and Older Suffered From Alcohol Use Disorder in 2018
Cybin (NEO: CYBN) (OTC: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has chosen Alcohol Use Disorder (AUD) as the initial target indication for its proprietary deuterated psychedelic tryptamine, CYB003. AUD is a chronic relapsing brain disorder characterized by an impaired ability to stop or control alcohol use despite negative social, occupational, or health consequences.
READ complete CYBN ARTICLE
4. Canopy Growth Signs U.S. dispensing Agreement with Southern Glazer’s Wine & Spirits for CBD Beverage Portfolio
The Company Will Tap into Southern Glazer’s Established dispensing Network to Bring Quatreau its CBD-Infused Sparkling Water, to U.S. Retailers
Canopy Growth (TSX: WEED) (NYSE: CGC) (FRA: 11L1) announced Southern Glazer’s Wine & Spirits, the world’s pre-eminent distributor of beverage alcohol, as the dispensing partner for its U.S. portfolio of CBD-infused beverages. This partnership announcement follows the recent set afloat of Quatreau – Canopy’s first line of CBD-infused beverages sold in the U.S market.
READ complete WEED ARTICLE
3. Numinus Announces Phase 1 Clinical Trial of Natural Psilocybin Mushroom Extraction Prepared at Company Lab
The Clinical Trial Will estimate the Safety and Psychoactive similarities of Natural Psilocybin Product Extracted and Formulated at the Company’s 7,000-Square-Foot Laboratory in British Columbia, Canada
Numinus Wellness (TSXV: NUMI) (OTC: LKYSD) (FRA: LR23), a mental health care company advancing inventive treatments and safe, evidence-based psychedelic-assisted therapies, announced today that it has formed a partnership with KGK Science, a leading contract research organization with skill in natural products, to attempt a new Psilocybin extraction clinical trial.
READ complete NUMI ARTICLE
2. Which Cannabis Stocks to Buy? Stick With U.S. Multi-State Operators
The U.S. is the Market to Be in, and There’s One Easy Way to Buy All the Most Promising Pot Stocks
The U.S. is the market investors should hang their hat on. Already, numbers here are crushing it in terms of both growth and revenue. What’s more amazing is cannabis isn’t already federally legal in addition. There is plenty of upside nevertheless to be had. These results can be seen in the recent quarterly earnings from a top name, Cresco Labs (CSE: CL) (OTCQX: CRLBF). These are numbers Canadian Licensed Producers (LPs) can only dream about. Other leading U.S Multi-State Operators (MSOs) include Curaleaf (CSE: CURA) (OTCQX: CURLF), Ayr Strategies (CSE: AYR.A) (OTCQX: AYRSF), and Green Thumb (CSE: GTII) (OTCQX: GTBIF) (FRA: R9U2). The fact these companies can’t list on the NASDAQ or NYSE is a disgrace, but I digress; consequently, the simplest approach is to buy the AdvisorShares Pure US Cannabis ETF (NYSEARCA: MSOS).
READ complete U.S. POT STOCKS ARTICLE
1. MindMed Surges Ahead of Nasdaq Debut
Per Company CEO J.R. Rahn, MindMed’s Mission is “to Discover, Develop and Deploy Psychedelic Inspired Medicines and Therapies to Address Addiction and Mental Illness”
Clinical-stage Psychedelic medicine and biotech company MindMed (NEO: MMED) (NASDAQ: MNMD) (FRA: MMQ) is surging again Monday ahead of its NASDAQ debut. MindMed announced last Friday it will be uplisted to the NASDAQ on Tuesday, leading to a 40% rise in proportion price.
READ complete MMED ARTICLE
Follow TCI on Social Media: Facebook | Instagram | Twitter | LinkedIn | Investor Group
Follow Psychedelic Profits on Social Media: Facebook | Twitter | LinkedIn | Investor Group
Source: The Cannabis Investor
The post Cannabis Countdown: Top 10 Marijuana and Psychedelic Stock News Stories of the Week appeared first on Trax News.
Click: See details